贝利尤单抗联合羟氯喹与泼尼松治疗系统性红斑狼疮患者的效果

Effects of Belimumab combined with Hydroxychloroquine and Prednisone in treatment of patients with systemic lupus erythematosus

目的:观察贝利尤单抗联合羟氯喹与泼尼松治疗系统性红斑狼疮患者的效果。方法:选取2021年3月至2023年3月该院收治的90例系统性红斑狼疮患者进行前瞻性研究,按随机数字表法将其分为对照组与研究组各45例。对照组采用羟氯喹联合泼尼松治疗,研究组在对照组基础上增加贝利尤单抗治疗。比较两组治疗前后疾病活动度[系统性红斑狼疮活动度指数(SLEDAI)]评分、免疫学指标[补体C3、补体C4、免疫球蛋白(Ig)G、IgA、IgM]水平、糖皮质激素服用剂量和不良反应发生率。结果:治疗后,两组SLEDAI评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组补体C3、补体C4水平均高于治疗前,且观察组高于对照组,两组IgG、IgA、IgM水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗第12、24周,两组糖皮质激素服用剂量均低于治疗第1周,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:贝利尤单抗联合羟氯喹与泼尼松治疗系统性红斑狼疮患者可降低SLEDAI评分,改善免疫学指标水平,减少糖皮质激素用量,其效果优于羟氯喹联合泼尼松治疗。

Objective:To observe effects of Belimumab combined with Hydroxychloroquine and Prednisone in treatment of patients with systemic lupus erythematosus.Methods:A prospective study was conducted on 90 patients with systemic lupus erythematosus admitted to the hospital from March 2021 to March 2023.According to the random number table method,they were divided into control group and study group,45 cases in each group.The control group was treated with Hydroxychloroquine combined with Prednisone,while the study group was treated with Belimumab on the basis of that of the control group.The disease activity[systemic lupus erythematosus activity index(SLEDAI)]score,the immunological indexes[complement C3,complement C4,immunoglobulin(Ig)G,IgA,IgM]levels,the Glucocorticoid dosage,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:After the treatment,the SLEDAI scores of the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of complement C3 and complement C4 in the two groups were higher than those before the treatment,and those in the observation group were higher than those in the control group;the levels of IgG,IgA and IgM in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;and the differences were statistically significant(P<0.05).12 and 24 weeks after the treatment,the doses of Glucocorticoids in the two groups were lower than those in thefirst week of treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Belimumab combined with Hydroxychloroquine and Prednisone in the treatment of the patients with systemic lupus erythematosus can reduce the SLEDAI scores,improve the levels of immunological indexes,and reduce the dosage of Glucocorticoids.Moreover,it is superior to Hydroxychloroquine combined with Prednisone treatment.